Optimized Fc variants and methods for their generation
The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
1. A protein comprising an Fc variant of a parent Fc polypeptide, said Fc variant comprising amino acid substitutions 239D, 332E, and 330L, wherein numbering is according to the EU index.
2. A protein according to claim 1 , wherein said protein is an antibody.
3. A protein according to claim 2 , wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, and a monoclonal antibody.
4. A protein according to claim 1 , wherein said Fc variant increases FcγRIIIa binding as compared to said parent Fc polypeptide.
5. A protein according to claim 1 , wherein said Fc variant increases FcγRIIa binding as compared to said parent Fc polypeptide.
6. A protein according to claim 4 , wherein said Fc variant increases ADCC as compared to said parent Fc polypeptide.
7. A protein comprising an Fc variant of a parent Fc polypeptide, said Fc variant comprising amino acid substitutions 239D, 332E, and 330L, wherein said protein increases binding affinity to an FcγR as compared to said parent Fc polypeptide and wherein numbering is according to the EU index.
8. A protein according to claim 7 , wherein said protein is an antibody.
9. A protein according to claim 8 , wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, and a monoclonal antibody.
10. A protein according to claim 7 , wherein said FcγR is FcγRIIIa.
11. A protein according to claim 7 , wherein said FcγR is FcγRIIa.
12. A protein according to claim 10 , wherein said Fc variant increases ADCC as compared to said parent Fc polypeptide.
13. An antibody or immunoadhesin each comprising an Fc variant of a parent Fc polypeptide, said Fc variant comprising amino acid substitutions 239D, 332E, and 330L in the Fc region of said antibody or immunoadhesin, wherein numbering is according to the EU index.
14. An antibody according to claim 13 .
15. An antibody according to claim 14 selected from the group consisting of a human antibody, a humanized antibody, and a monoclonal antibody.
16. An antibody or immunoadhesin according to claim 13 , wherein said antibody or immunoadhesin has increased binding affinity for an FcγR as compared to the antibody or immunoadhesin without said amino acid substitutions.
17. An antibody or immunoadhesin according to claim 16 , wherein said FcγR is FcγRIIIa.
18. An antibody or immunoadhesin according to claim 16 , wherein said FcγR is FcγRIIa.
19. An antibody or immunoadhesin according to claim 17 , wherein said antibody or immunoadhesin increases ADCG as compared to said parent Fc polypeptide.